alexa Mesenchymal Stem Cells To Repair Vascular Damage After Chemotherapy: Past, Present And Future
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Cell & Gene Therapy
October 27-29, 2014 Embassy Suites Las Vegas, USA

Sulaiman Al-Hashmi
ScientificTracks Abstracts: J Stem Cell Res Ther
DOI: 10.4172/2157-7633.S1.007
The use of hematopoietic stem cell transplantation (HSCT) is continuously expanding to cover a broader range of diseases. Because HSCT implicates the immune system, the new cells from the donor cannot be engrafted without compromising the recipient immune system. Currently, approximately 50% of patients undergoing HSCT are conditioned with chemotherapy. Although the chemotherapeutic regimens have improved the outcomes of transplanted or cancer patients they have been associated with severe side effects that can considerably compromise the quality of patients? life. Recent studies have shown that even short-term chemotherapy can cause vascular injury that leads to potential adverse cardiac effects, including heart failure and hypertension. Mesenchymal stem cells (MSC) therapy could be a promising procedure to reduce vascular damage and increase tissue repair as these cells are endowed with a potent tissue regeneration capacity along with immunosuppressive properties. MSC therapy can decrease cardiotoxicity and improve vascular repair following chemotherapy regimens. Additionally, MSC infusion can influence the function of the endothelial cells and the level of the growth factors, inflammatory cytokines and immune cells. Collectively, understanding of MSC as a pharmacological tool to repair vascular damage and other organ dysfunction following chemotherapy in HSCT or cancer patients is of paramount importance to develop effective protocols.
Sulaiman Al-Hashmi received his PhD degree from Karolinska Institutet in 2011. He is managing the National Tissue Typing Laboratory in Sultanate of Oman. His current work is focused on the use of MSC on tissue repair and regenerative medicine. He has published several papers in peer reviewed journals.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version